Eli Lilly and Company $LLY Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its stake in Eli Lilly and Company (NYSE:LLY) by 3.3% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 3,895,925 shares of the company’s stock after buying an additional 124,352 shares during the quarter. Eli Lilly and Company comprises 0.7% of Dimensional Fund Advisors LP’s portfolio, making the stock its 12th largest holding. Dimensional Fund Advisors LP’s holdings in Eli Lilly and Company were worth $3,582,704,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company in the fourth quarter worth approximately $25,000. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $30,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares in the last quarter. Finally, Dorato Capital Management acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $36,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
• Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984
• Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal
• Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on LLY shares. Sanford C. Bernstein boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 14th. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, July 1st. UBS Group upped their price objective on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company Trading Down 0.1%

NYSE LLY opened at $1,178.01 on Monday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm’s fifty day moving average price is $1,118.87 and its 200 day moving average price is $1,036.51. The company has a market capitalization of $1.11 trillion, a price-to-earnings ratio of 41.85, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 34.55 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.